Company logo

CERE - Cerevel Therapeutics Holdings, Inc.

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United States
Type: Equity

CERE price evolution
CERE
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $418.43 $157.68 $177.72 $155.68
Short term investments $574.5 $521.16 $560.66 $673.17
Net receivables $5.29 $3.41 $4.13
Inventory
Total current assets $1006.94 $687.79 $751.67 $840.78
Long term investments $185.2 $81.34 $88.64 $36.05
Property, plant & equipment $45.77 $47.19 $48.26 $48.44
Goodwill & intangible assets
Total noncurrent assets $236.36 $134.18 $142.68 $89.56
Total investments $759.7 $602.5 $649.3 $709.22
Total assets $1243.3 $821.96 $894.35 $930.35
Current liabilities
Accounts payable $11.86 $11.54 $9.39 $7.32
Deferred revenue
Short long term debt $3.4 $3.28 $3.15 $3.03
Total current liabilities $92.18 $78.84 $65.56 $62.96
Long term debt $477.37 $470.16 $478.29 $435.68
Total noncurrent liabilities $477.37 $470.16 $478.29 $435.68
Total debt $480.78 $473.44 $481.44 $438.71
Total liabilities $569.55 $549 $543.85 $498.64
Shareholders' equity
Retained earnings -$1400.6 -$1267.94 -$1171.58 -$1072.04
Other shareholder equity $1.77 $1.68 $1.14 $3.69
Total shareholder equity $673.75 $272.96 $350.5 $431.71
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $418.43 $138.39 $197.22 $387.82
Short term investments $574.5 $755.51 $372.67
Net receivables $5.29 $2.05
Inventory
Total current assets $1006.94 $905.65 $578.02 $390.56
Long term investments $185.2 $58.13 $52.27
Property, plant & equipment $45.77 $49.29 $51.7 $48.62
Goodwill & intangible assets
Total noncurrent assets $236.36 $112.17 $110.9 $54.71
Total investments $759.7 $813.63 $424.94
Total assets $1243.3 $1017.82 $688.92 $445.27
Current liabilities
Accounts payable $11.86 $10.06 $11.3 $4.99
Deferred revenue
Short long term debt $3.4 $2.9 $2.44 $2.04
Total current liabilities $92.18 $72.56 $42.54 $29.55
Long term debt $477.37 $335.48 $67.65 $30.97
Total noncurrent liabilities $477.37 $424.02 $67.65 $31.2
Total debt $480.78 $426.92 $70.09 $33.01
Total liabilities $569.55 $496.58 $110.19 $60.75
Shareholders' equity
Retained earnings -$1400.6 -$967.75 -$616.24 -$390.91
Other shareholder equity $1.77 $3.1 -$0.99
Total shareholder equity $673.75 $521.24 $578.73 $384.52
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $97.13 $85.25 $74.08 $78.18
Selling, general & administrative $42.44 $26.05 $22.76 $21.37
Total operating expenses $139.56 $111.31 $96.84 $99.55
Operating income -$139.56 -$111.31 -$96.84 -$99.55
Income from continuing operations
EBIT -$129.82 -$93.59 -$96.79 -$110.64
Income tax expense $0.19 $0.12 $0.11 $0.09
Interest expense $2.65 $2.64 $2.64 -$6.44
Net income
Net income -$132.66 -$96.36 -$99.53 -$104.29
Income (for common shares) -$132.66 -$96.36 -$99.53 -$104.29
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $334.64 $280.26 $161.85 $103.3
Selling, general & administrative $112.62 $87.59 $58.24 $45.81
Total operating expenses $447.26 $367.85 $220.1 $149.12
Operating income -$447.26 -$367.85 -$220.1 -$149.12
Income from continuing operations
EBIT -$421.77 -$360.97 -$225.33 -$152.17
Income tax expense $0.5 $0.16 -$0.02
Interest expense $10.57 -$9.62
Net income
Net income -$432.84 -$351.51 -$225.33 -$152.14
Income (for common shares) -$432.84 -$351.51 -$225.33 -$148.27
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$132.66 -$96.36 -$99.53 -$104.29
Operating activities
Depreciation $1.5 $1.45 $1.35 $1.32
Business acquisitions & disposals
Stock-based compensation $25.22 $17.09 $14.51 $12.59
Total cash flows from operations -$97.42 -$72.63 -$77.33 -$94.92
Investing activities
Capital expenditures -$0.9 -$0.51 -$2.06 -$0.34
Investments -$149.31 $51.91 $63.81 $111.12
Total cash flows from investing -$150.21 $51.39 $61.75 $110.78
Financing activities
Dividends paid
Sale and purchase of stock $508.37 $1.2 $6.36 $1.57
Net borrowings $31.25
Total cash flows from financing $508.37 $1.2 $37.61 $1.44
Effect of exchange rate
Change in cash and equivalents $260.74 -$20.04 $22.04 $17.3
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$432.84 -$351.51 -$225.33 -$152.14
Operating activities
Depreciation $5.63 $4.9 $2.73 $0.4
Business acquisitions & disposals
Stock-based compensation $69.41 $38.78 $23.94 $10.26
Total cash flows from operations -$342.3 -$293.19 -$178.55 -$117.8
Investing activities
Capital expenditures -$3.81 -$3.95 -$10.5 -$18.89
Investments $77.53 -$384.88 -$425.16
Total cash flows from investing $73.72 -$388.83 -$435.66 -$18.89
Financing activities
Dividends paid
Sale and purchase of stock $517.5 $251.31 $337.1 $442.62
Net borrowings $31.25 $372.27 $31.25
Total cash flows from financing $548.62 $623.19 $423.6 $440.83
Effect of exchange rate
Change in cash and equivalents $280.04 -$58.83 -$190.6 $304.14
Fundamentals
Market cap $7.69B
Enterprise value $7.75B
Shares outstanding 181.36M
Revenue $0.00
EBITDA -$425.22M
EBIT -$430.85M
Net Income -$432.84M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -17.76
EV/Sales N/A
EV/EBITDA -18.22
EV/EBIT -17.98
P/S ratio N/A
P/B ratio 11.44
Book/Share 3.71
Cash/Share 2.31
EPS -$2.39
ROA -44.51%
ROE -100.14%
Debt/Equity 0.85
Net debt/EBITDA -0.36
Current ratio 10.92
Quick ratio 10.92